NCT05027139: A Study of Zanidatamab (ZW25) With ALX148 in Patients With Advanced HER2-expressing Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have had progression after or during the most recent systemic regimen of treatment for advanced cancer
Exclusions: Patients with HER2+ breast cancer that have not received Herceptin or Perjeta; Patients with HER2-low who HAVE received prior HER2-targeted therapy; Patients with untreated or symptomatic brain metastases- see trial for details; Patients with leptomeningeal disease; Patients with prior treatment of any anti-CD47 or anti-signal regulatory protein alpha (SIRPa) agent

Comments are closed.

Up ↑